Clinical trials: Growth, open to volunteers
Breast Cancer
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or…
- Trial name
- NCT07003074
- Testing
- TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab
- Where
- 25 sites in China
- Volunteers
- 642 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally…
- Trial name
- TROPION-Lung14 (NCT06350097)
- Testing
- Osimertinib, Datopotamab Deruxtecan
- Where
- 167 sites in United States, Australia and 17 more
- Volunteers
- 582 people
- Sponsor
- AstraZeneca
Malnutrition, Infant, Breastfeeding, Exclusive
Providing Breastfeeding Support After Discharge From Hospital to Improve Growth and Development of Malnourished Infants
The current guidelines used to manage malnutrition among infants aged below 6 months (u6m) recommend that infants admitted to hospital with malnutrition be supported to reestablish exclusive breastfeeding before discharge.
- Trial name
- IBAMI-2 (NCT06372418)
- Testing
- Breastfeeding peer support intervention, Standard Care
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Healthy, Obesity & Overweight
Growth Hormone Resistance of Beta-cells
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired…
- Conditions
- Healthy, Obesity & Overweight, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (Prediabetes)
- Trial name
- GHRB-C (NCT07581860)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Breast Neoplasms
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer.
- Trial name
- preEMBER (NCT07287098)
- Testing
- Imlunestrant, Goserelin, Tamoxifen 20 mg
- Where
- 90 sites in United States, Belgium and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
NSCLC Stage IV
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival.
- Trial name
- NCT05215548
- Testing
- therapeutic thoracic surgery, Afatinib
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Growth Alteration
Catch up Growth Of Children After Closure Of Hemodinamically Significant Large VSD In Assuit University Children Hospital
The primary objective of this study is to evaluate the patterns of catch-up growth in children following the closure of large VSDs.
- Trial name
- NCT07515248
- Where
- Egypt
- Volunteers
- 58 people
- Sponsor
- Assiut University
Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast…
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- ALISCA-Breast1 (NCT06369285)
- Testing
- Alisertib, Endocrine therapy
- Where
- 53 sites in United States, Portugal and 1 more
- Volunteers
- 225 people
- Sponsor
- Puma Biotechnology, Inc.
Mild Cognitive Impairment
Low-intensity Physical-cognitive Exercise and Cognitive Function
This study aims to examine the effects of low-intensity, combined physical-cognitive exercise on cognitive function of older people with mild cognitive impairment (MCI) and identify the mechanisms by which this exercise protocol…
- Trial name
- NCT06201533
- Testing
- combined physical-cognitive exercise
- Where
- Thailand
- Volunteers
- 64 people
- Sponsor
- Chiang Mai University
Puberty, Precocious, Breast
Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context
Various studies show an increase in the number of cases of early puberty in girls with breast development with a variable clinical presentation and evolution. This increasing phenomenon concerns girls between 6 and 8 years old.
- Conditions
- Puberty, Precocious, Breast, Environmental Exposure
- Trial name
- PENELOPE (NCT06083415)
- Testing
- Environmental health measures
- Where
- 2 sites in France
- Volunteers
- 62 people
- Sponsor
- Lille Catholic University
Biliary Tract Cancer
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
The primary purpose of this study is to investigate the safety of Tasfygo.
- Trial name
- NCT06793709
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Eisai Co., Ltd.
Healthy Infants
Growth, Tolerance, and Functional Biomarkers in Healthy Infants Receiving Dietary Supplements
This is a double-blind, randomized, placebo-controlled nutritional study aimed at investigating growth, tolerance, and functional biomarkers in healthy infants receiving dietary supplements from birth to 2.5 months of age
- Trial name
- NCT07630584
- Testing
- Probiotic dietary supplement
- Where
- 2 sites in Philippines
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Gut Microbiome, Neurocognitive Correlates of Eating Habits
Early Avocado Exposure on Development and the Gut Microbiome in American Hispanic Infants
The goal of this clinical trial is to learn if daily avocado intake can improve growth and brain and gut health in infants. The main questions it aims to answer are: Does daily eating of avocados change which microbes live in the…
- Conditions
- Gut Microbiome, Neurocognitive Correlates of Eating Habits, Infant Growth
- Trial name
- Guac & Grow (NCT06876935)
- Testing
- Daily avocado
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Hypochondroplasia
Prospective Clinical Assessment Study in Children With Hypochondroplasia
This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).
- Trial name
- HCH (NCT06410976)
- Where
- 25 sites in United States, Australia and 8 more
- Volunteers
- 150 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Fetal Growth Restriction (FGR), Preterm Birth
Enhancing Prediction of Adverse Pregnancy Outcomes in Africa Through Partnerships and Innovation
Pregnancy complications such as pre-eclampsia (high blood pressure during pregnancy), poor fetal growth, unexplained stillbirth, and spontaneous preterm birth are major causes of illness and death for mothers and babies in…
- Conditions
- Fetal Growth Restriction (FGR), Preterm Birth, Still Births, Abruptio Placentae
- Trial name
- EPAPOA (NCT07844876)
- Where
- 2 sites in Uganda
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Makerere University
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with…
- Conditions
- Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
- Trial name
- NCT07154290
- Testing
- Ubamatamab, Marlotamig, Sarilumab
- Where
- 18 sites in United States
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Lazertinib
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
Using gefitinib or Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with active mutations in epithelial cell growth factor receptors (EGFR), 70% response rate (CR+PR) and 90% disease control rate (CR+PR+SD)…
- Trial name
- NCT06156527
- Testing
- Lazertinib, Bevacizumab Injectable Product
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- National Cancer Center, Korea
Metastatic Breast Cancer
HER2-positive Metastatic Breast Cancer in Kazakhstan
Planned study population consists of approximately 240 adult patients with HER2-positive mBC receiving anti-HER2 therapy in 12 oncological centers (in each center it is expected to recruit about 20 patients) in different regions…
- Trial name
- NCT07593196
- Where
- 12 sites in Kazakhstan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Cholangiocarcinoma, Bile Duct Neoplasm
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Background: Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few treatment options and poor survival. Researchers want to see if a new drug can stop or slow CCA growth.
- Conditions
- Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
- Trial name
- NCT04645160
- Testing
- Tivozanib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Vestibular Disorder, Neurodevelopmental Disorders
BALANCED GROWTH: The Involvement of the Vestibular System in a Child's Cognitive and Motor Development
When a vestibular dysfunction occurs at birth or in early stages of life, one might expect that this may have an enormous impact on a child's development.
- Trial name
- NCT04685746
- Testing
- Balanced Growth Protocol
- Where
- Belgium
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Ghent